tbuckley/cabot-search huggingface dataset:
Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger.
Authors: D. Rey-Herin, A. D. Bouhnik, S. Cortaredona, V. Seror, M. K. Bendiane, Y. Odadia, P. Viens
Journal: Journal of Clinical Oncology (2010)

643 Background: Long-term adjuvant endocrine treatment (AET) improves survival in women with breast cancer, but little is known on adherence to such therapy, especially among young women. Our aim was to evaluate the rate of adherent patients among young breast cancer women who had been prescribed an AET, using both women's self-report and medication reimbursement database. Methods: Since July 2005, all consecutive women included in the registry of the French Health Insurance Fund (NHIF) for a diagnosis of primary breast cancer, aged 18-40 and living in South Eastern France have been asked to participate in a 5-year follow-up. Data about AET delivery are collected through the NHIF database. Women were identified as adherent if until the 28-month interview, they were delivered at least 80% of the total treatment on a minimum period of 15 months, and if the period between 2 deliveries did not exceed 3 months. Self-reported adherence was defined as the reported consumption of > = 80% of prescribed AET at each phone interview (10, 16, and 28 months after diagnosis) Results: Until November 2009, 202 women had a 28-month follow-up after breast cancer diagnosis, 135 were prescribed an AET. 25.2% had a stage II tumour, and 25.3% a stage III. All had surgery, 86.7% chemotherapy and 92.6% radiotherapy. During follow-up 54% were prescribed only anti-oestrogens, 39% anti-oestrogens and/or aromatase inhibitors and GnRH antagonists. Only 7% were never prescribed anti-oestrogens. According to self-report, 69.6% of women were adherent to AET during all follow-up. Based on medication delivery, only 37% of women were adherent during the same period. Women who received anti-oestrogens were more likely to be adherent than those who received other AET (48.9% vs. 14.9%, p < 10-3). Nonadherence was more frequent in women with higher tumour stages and in those unsatisfied with the information provided by the physician in charge of cancer management Conclusions: A majorityof young women were not adherent to AET 2 years after breast cancer diagnosis. The real world treatment adherence in this young population was notably lower than reported in previous studies in post menopausal women. Strategies are really needed to improve treatment adherence among young women. No significant financial relationships to disclose.
Delayed oral toxicity from long-term vemurafenib therapy
Authors: A. Lloyd-Lavery, T. Hodgson, N. Coupe, S. Bond, K. Shah, O. Espinosa, M.J. Payne, M.R. Middleton, R.N. Matin
Journal: British Journal of Dermatology (2016)

We read with interest the article by Vigarios et al.1 describing eight patients treated with a variety of BRAF inhibitors who developed asymptomatic hyperkeratotic oral mucosal lesions. These were frequently multifocal and presented following a mean onset of three months of treatment with a BRAF inhibitor. In one patient, one such lesion rapidly developed into oral squamous cell carcinoma requiring excision. We would like to highlight delayed oral toxicity in a long-term responder to a BRAF inhibitor.
Induction of Tumors in Rats by Oral Administration of Technical Acid Violet 6B
Authors: Kunio Uematsu, Toru Miyaji
Journal: JNCI Journal of the National Cancer Institute (1973)

Sprague-Dawley rats of both sexes were fed diets containing commercial 5% acid violet 68 for 1 year. Five mammary carcinomas and 4 ear-duct carcinomas developed in 9 of 18 female rats. No tumors were observed in males.
Promoting Effect of Bile Acids on Colon Carcinogenesis After Intrarectal Instillation of N -Methyl- N ′ nitro- N -nitrosoguanidine in Rats 2
Authors: Tomio Narisawa, Napoleon E. Magadia, John H. Weisburger, Ernst L. Wynder
Journal: JNCI Journal of the National Cancer Institute (1974)

The effect of 2 bile acids in colon carcinogenesis was studied in rats. A single dose of N-methyl-N′nitro- N-nitrosoguanidine (MNNG) was instilled intrarectally. Subsequently, repeated intrarectal doses of lithocholic or taurodeoxycholic acid were administered. Both bile acids increased the frequency of MNNG-induced colorectal neoplasms. Neither bile acid induced tumors when used alone. The lesions were like those induced by MNNG alone and included adenomas and adenocarcinomas. The bile acids acted as promoters of carcinogenesis.
The Differential Susceptibility Hypothesis
Authors: Jay Belsky
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Coping with uncertainty: A qualitative study of 33 palliative care consultations among patients with advanced cancer.
Authors: Mohamedtaki Abdulaziz Tejani, Charles Stewart Kamen, Supriya Gupta Mohile, Robert E. Gramling
Journal: Journal of Clinical Oncology (2014)

92 Background: Despite scientific advances, uncertainty remains an inherent and significant issue in clinical practice. Among patients with advanced cancer, uncertainty about the future can lead to distress, loss of sense of control and lower quality of life. Helping patients manage uncertainty is a core domain of patient-centered care. Little is known about how palliative care providers work with cancer patients to accomplish this goal. Methods: We performed descriptive analysis of transcripts from audio recorded inpatient palliative care consultations among adult cancer patients referred for ‘goals of care’ or ‘end of life decision making.’ Each transcript was read as a whole and then again line by line to code verbal expressions of uncertainty. Excerpted segments dealing with uncertainty about the future were grouped and analyzed by an experienced qualitative research working group. Results: 33 consultations were analyzed: 53% men, median age 62 and median survival 3.6 weeks. Multiple expressions of uncertainty were identified – 106 by patients/families and 56 by providers. A majority (63%) were centered on the inevitable uncertainty in predicting clinical course at the end of life. Palliative care providers managed this type of uncertainty in three main ways: (a) pairing expressions of unpredictability with reiteration of what was certain/known at time of consultation (e.g. ‘we will not let you suffer’); (b) utilizing inherent uncertainty of future to promote hope and faith (e.g. ‘nobody knows how long you are going to live’) and (c) reassurance that multi-disciplinary providers would convene to provide consensus and clarity for next visit (e.g. ‘we will all put our heads together and come up with exactly which options are available.’). Conclusions: Uncertainty is highly prevalent during end of life consultations with advanced cancer patients. Palliative care providers use validating strategies to help patients acknowledge and cope with what is inherently uncertain about their future. These methods can be used to develop communication training and guidelines for use with advanced cancer patients at the end of life.
Phase 1 Dose Escalation and Cohort Expansion Study of the Safety of Intrathecal Trastuzumab in Her2 Positive Parenchymal Brain Metastatic Breast Cancer: Trial Protocol
Authors: J. Savva-Bordalo, A.C.F. Rodrigues, J. Oliveira, D. Pereira, N. Afonso
Journal: Annals of Oncology (2014)
원저 : 경간동맥화학색전술을 시행한 간세포암 환자에서 재발인자 및 예후 분석
Authors: 금민수(Min Su Geum), 김대현(Dae Hyun Kim), 탁원영(Won Young Tak), 권영오(Young Oh Kweon), 김성국(Sung Kook Kim), 최용환(Yong Hwan Choi), 정준모(Joon Mo Chung)
Journal: Clinical and Molecular Hepatology (2000)

Background/Aims : Hepatocellular carcinoma (HCC) is a malignant tumor with very poor prognosis if left untreated after diagnosis. However, recent advances in digital subtraction imaging techniques and superselective catheterization seem to have somewhat increased the survival rate in patients with HCC after transarterial chemoembolization (TACE). This study analyzed the relationship between prognostic factors and recurrence after TACE, an aspect which has not attracted much attention. Methods : This investigation included 258 cases of HCC with 100% lipiodol uptake who received TACE for a duration of 13 years from 1985 to 1997. Clinical characteristics, biochemical factors, tumoral factors, angiographic characteristics, embolization technique, degree of lipiodol uptake, response, and recurrence factors were analyzed retrospectively. Results : Significant differences in survival were noted among 3 groups according to cancer-free interval (p<0.01). The different factors between early recurrence group (within 6 months) and late recurrence group (after 18 months) were initial tumor size (8.8±4.1/6.1±3.7cm, p<0.01), tumor type (multinodular,massive/single nodule, p<0.01), ill-defined margin (51.4/22.0%, p<0.01), response after TACE (NC/CR,PR, p<0.01), ALP level (196.1±124.5/144.4±72.0 IU/L, p<0.05), absence of encapsulation (42.3/25.0%, p<0.05), portal vein thrombosis (64.3/14.3%, p<0.05), nonsegmental embolization (46.6/25.0%, p<0.05), post-TACE AFP level (180.5±252.1/76.6±329.8 ng/mL, p<0.05), and recurrence pattern (revascularization of initial lesion/single nodule, p<0.05). Conclusions : Recurrence factors were significant in the survival of patients with HCC after TACE. Therefore, an understanding of the relationship between prognostic factors and recurrence is very important for early detection of recurrence and the timely provision of further TACE treatment. (Korean J Hepatol 2000;6:111－123)
Macrolides vs quinolones in Legionella pneumonia treatment: CAPAVANT group. Valencia (Spain)
Authors: Susana Herrera, Estrella Fernández, Angela Cervera, M. Carmen Aguar, Francisco Sanz, Jose Blanquer, Eusebi Chiner
Journal: European Respiratory Journal (2012)

Background There is not data enough to assure Quinolones are more effective than Macrolides in Legionella pneumonia treatment (CAP-L). We analyzed differences at CAP-L evolution related to the antibiotic employed. Method: 12 months prospective, multicenter and longitudinal study in 10 hospitals of a Spanish area, enrolling consecutive CAP patients. Differences in illness severity scores (PSI and CURB65), clinical-radiological findings, length of hospital stay (LOS), outcomes, and mortality were analyzed in a subgroup of CAP-L patients, divided in two groups: Group A CAP-L treated with Macrolides and Group B treated with Quinolones. Statistics: Independent-samples T test and X2  test. Results: From 1314 cases of CAP, 11,2% were CAP-L, 70,1% men, mean age 62,23 ±16 years old. 37,2% were included in Group A and 54,7% in Group B. 89,9% of cases were admitted in hospital for treatment, with LOS of 8,9±6,7 days, and no differences between the two groups (A 8,33± 4,2 days vs B 9,15±6,8, p=0.52). No differences were observed in clinical or radiological data, neither in blood gas analysis nor illness severity by PSI or CURB65 scores at admittance between the two groups. Evolution time until treatment administration was 4,63±2,8 days (A 4,85±3,17 vs B 4,52±2,73 days; p=0.74). Clinical evolution was similar in two groups with ICU admittance in 6,1% (A 5,5% vs B 7,4%, p=0.58), mechanical ventilation in 4,1% (A 3,6% vs B 4,9%, p=0.7), respiratory failure in 10,1% (A 10,9% vs B 8,6%, p=0.67), and death in 3,4% (A 5,5% vs B 1,2%; p= 0.25). Conclusion: In our experience, evolution of CAP-L patients is similar, if they are both treated with Macrolides or with Quinolones, with a low global mortality rate.
Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study
Authors: G. Pica, S. Nati, Umberto Vitolo, Sara Galimberti, Pier Luigi Zinzani, Nicola Cascavilla, Mario Petrini, A. M. Carella
Journal: Blood (2011)
Assessing compliance with practice treatment guidelines by treatment centers and the reasons for noncompliance
Authors: J. J. Biagi, R. Wong, J. Brierley, R. Rahal, J. Ross
Journal: Journal of Clinical Oncology (2009)

e17506 Background: Cancer Care Ontario (CCO) is the chief advisor on cancer care to the government of Ontario, a province with a population of more than 12 million. One of the many roles of CCO is to develop evidence based consensus-derived treatment practice guidelines for all major cancer types, through its Program in Evidence-based Care (PEBC). To determine province-wide compliance with these guidelines, a pilot project assessed the proportion of patients with stage III colon cancer (CC) treated in concordance with the corresponding treatment guideline. Initial results are made available to the regional cancer centers (RCC) in the province and to the public through web based Cancer Systems Quality Index (CSQI, http://www.cancercare.on.ca/qualityindex2007/ ). Methods: The guideline (http://www.cancercare.on.ca/pdf/pebc2–29s.pdf) states that patients with resected stage 3 CC will have adjuvant fluoropyrimidine-based chemotherapy within eight weeks of resection. Patients at each of 11 RCC who presented in 2007/2008 with stage III CC and the proportion treated according to the guidelines were identified. Individual charts of those patients who were not treated according to guideline were reviewed to determine the reason. Results: Across eight RCC with complete chart results to date 376 patients with stage 3 CC were identified, 244 (65%, range 47% to 72%) treated in concordance with the guideline, including 13% treated with capecitabine and 6% on clinical trials. The reasons for non-concordance of the 132 remaining cases were: age and co morbid conditions 48 (13%), patient choice 36 (10%), referred for treatment outside the RCC system 16 (4%), stage incorrect and other 32 (9%). Conclusions: Adjuvant chemotherapy treatment of stage III CC at the RCC across the Province of Ontario was concordant with the guideline in the majority of patients, and appropriate clinical reasons for non-compliance were identified. Data from all 11 RCC will be presented along with concordance within the eight-week time frame stated in the guideline . Refinement in province-wide data collection and interpretation will allow results from this pilot to be expanded to other PEBC practice guidelines for dissemination through the CSQI. No significant financial relationships to disclose.
Angiogenesis: Angiogenic Type I Collagen Extracellular Matrix Integrated with Recombinant Bacteriophages Displaying Vascular Endothelial Growth Factors (Adv. Healthcare Mater. 2/2016)
Authors: Junghyo Yoon, Nuriye Korkmaz Zirpel, Hyun‐Ji Park, Sewoon Han, Kyung Hoon Hwang, Jisoo Shin, Seung‐Woo Cho, Chang‐Hoon Nam, Seok Chung
Journal: Advanced Healthcare Materials (2016)

The cover image displays vascular endothelial growth factors (purple and green beads), bacterio-phages (blue rods), and their integration on the type 1 collagen extracellular matrix fibers (gray/white fiber bundles). On page 205, C.-H. Nam, S. Chung, and co-workers show that the integration of growth factors is easy and very stable, and that angiogenesis is induced in vitro and in vivo.
Quality of life and quality of care in cancer survivors: Fear of cancer recurrence—Preliminary results of a transcultural availability of validated tools.
Authors: R. Ciotti, S. Simard, A. Ardizzoia, M. Visini, I. Vittimberga, I. Colombo, E. Traverso
Journal: Journal of Clinical Oncology (2010)

e19675 Background: Cancer survivors are faced with physical and psychological problems. In follow-up care we have to give greater attention to the quality of life. The fear of cancer recurrence (FCR) is one the most disturbing aspects, resulting in pointless examinations and one of the most prevalent areas of unmeet needs. Yet few efforts have been made to better understand this phenomenon and to work out a validated measures. The goal of this study was to develop the Italian version of the Fear of Cancer Recurrence Inventory (FCRI). Methods: The FCRI is a multidimensional 42-items questionnaire evaluating seven fear components: Triggers, Severity, Psychological distress, Functioning impairments, Insight, Reassurance and Coping strategies. It was initially worked out and validated with French-speaking Canadian cancer survivors (Simard & Savard Supp Care Cancer 2009 17:241-251). A forward-backwards procedure was used to translate the original FCRI into Italian, then it was pilot tested in fifty Italian cancer survivors to assess face and content validity. Results: The partecipants were able to identify correctly the general content being measured (i.e. good face validity). Italian FCRI was considered to be clear, useful, simple to use and no time consuming; it could help to investigate the fears of patients facilitating the communication with physicians. It was found to be distressful only by one partecipant, but this was associated with a recent death of a relative. Partecipants were happy to collaborate in a project that could help other patients. 16% of interviewed suggested questions about God in coping strategies; in their mind God represents an important support to fight their fears. Conclusions: These findings provide preliminary evidence about the usefulness and the utility of FCRI in people with different culture. Further studies are needed to assess its validity and its transcultural availability. If cancer treatments move from cytotoxic agents to molecular ones, Physicians need to take care of survivors exploring more global perspectives. FCRI will be released at sebastien.simard@criucpq.ulaval.ca No significant financial relationships to disclose.
Breast feeding reduces morbidity [editorial]
Authors: Latham Mc
Journal: BMJ (1999)

Since breast milk contains immunoglobulins phagocytes and other factors that protect the infant against infection infants who are breast-fed have much lower rates of morbidity and mortality than those who are artificially fed.  This has been demonstrated in a recent study in Brazil showing that breast-feeding protected infants against pneumonia.  This study reported that infants who were not receiving breast milk were 17 times more likely to present with pneumonia than those receiving breast milk but no artificial milk.  The results further indicate that breast-feeding protects infants against pneumonia at all ages but gives greater protection in younger infants.  However the value of breast-feeding is currently under scrutiny due the fact that HIV may be transmitted to the infant through breast milk.  Although there is a small risk that an HIV positive mother will infect her infant through breast-feeding a much greater risk is seen when there will be an inappropriate rush to replace breast-feeding with formula feeding especially in developing countries with high HIV prevalence.  Considering that artificial feeds substantially increases childrens risk of death and illness risk reduction of HIV transmission should focus more on risk assessment rather than a shift to formula feeds.
Abstract 306: Use of Real-Time Audiovisual CPR Feedback is Associated With Improved CPR Quality During Patient Transfer From the Scene to the Ambulance in Out-of-Hospital Cardiac Arrest
Authors: Tyler Vadeboncoeur, Annemarie Silver, Ryan Anne Murphy, Sungwoo Moon, John Tobin, Mark Venuti, Madalyn Karamooz, Daniel Spaite, Bentley Bobrow
Journal: Circulation (2013)

Background: In the simulation setting, chest compression (CC) quality is reduced when out-of-hospital cardiac arrest “patients” are prepared for transport (i.e. packaged and moved to ambulance). It is unknown whether use of real-time audiovisual CPR feedback (RTAVF) affects manual CC quality when the patient is prepared for transport during actual out-of-hospital resuscitations. We tested the hypothesis that CC quality during patient transfer would be better when using RTAVF. Methods: CC quality was monitored at two EMS agencies using an E Series monitor/defibrillator with CC sensing capability (ZOLL Medical) during the treatment of consecutive out-of-hospital cardiac arrest patients who received CC on scene and were transported with ongoing CC. Data were collected during study phases; P1: RTAVF disabled, P2: RTAVF enabled following scenario-based training. Student’s t-test and Wilcoxon-Mann Whitney tests were used to compare CC quality in P1 vs. P2 during early scene and late scene treatment. Late scene was defined as the 3 minutes prior to transport (when packaging and transfer to the ambulance occurs) and early scene was all prior minutes at the scene. Results: 211 cardiac arrest cases were included: mean age 64±15 yrs, 67% male, 8% survival to hospital discharge. The Table shows that CC quality was superior during both early scene and late scene treatment in P2, when RTAVF was enabled, vs. P1, when RTAVF was disabled. Conclusion: CC quality, particularly the CC fraction, declines when a patient is packaged for transport and moved to the ambulance. While this decline is not prevented by RTAVF, CC quality during the late scene period is significantly better when using RTAVF. Further study is required to determine the impact of this improvement on outcomes.